tbuckley/cabot-search huggingface dataset:
Monocentric evaluation of erlotinib in advanced prostate cancer
Authors: G. Gravis, A. Gonçalves, F. Bladou, N. Salem, B. Esterni, S. Bagattini, P. Viens
Journal: Journal of Clinical Oncology (2007)

15569 Background: The human epidermal growth factor receptor (HER1/EGFR) is known to be over expressed in a variety of cancers, including prostate cancer. Erlotinib is an orally active small molecule tyrosine kinase inhibitor (TKI) targeted against HER1/EGFR (ErbB1). Methods: Pts with advanced or metastatic prostate cancer, adequate organ function and Karnofsky performance status (KPS) ≥ 50% were enrolled in a phase II single institution study. Pts were required to have documented PSA progression before study entry. The primary objective was to determine the efficacy of erlotinib defined as a decrease or stabilization of PSA. Pts received erlotinib 150 mg/day; if no acceptable toxicity was reported in the first 3 weeks, the dose was increased to 200 mg at week 4, and continued until disease progression or unacceptable toxicity. Results: Thirty patients were treated between April 2004 and February 2006, Median age was 69 years (range 51–77) median KPS was 80 (70–100). Median PAL was 85 UI/L (range 33–732), median LDH 224 UI/L (144–1,016) and PSA 102 ng/ml (3, 4–1213). Twenty-eight pts had metastatic disease, 2 had PSA relapse only and 29 were androgeno-independant. Twenty three had received prior chemotherapy (median 2 lines, range (1–7)). Dose escalation was possible in 16 (55%) pts and median duration of treatment was 60 days (14–99). The most common grade 3 toxicities were fatigue (3 ), anaemia (2), diarrhea (2) vomiting (2) cutaneous toxicity (1); one pt. had grade 4 anemia. Median PFS was 29 days (IC 95 [28–33]), median OS 17,38 months. PSA stabilization was observed in 4 pts; no pt had a decrease in PSA. Clinical benefit evaluation based on KPS and pain was achieved in 8 of 20 evaluable pts (40%). Conclusion: Erlotinib demonstrated some activity in advanced prostate cancer with 14% of pts achieving PSA stabilization and 40% a clinical benefit. Erlotinib was well tolerated. Future directions might include evaluating its use in less advanced disease and in pts with EGFR kinase domain mutations. Understanding which biomarkers predict response to erlotinib will likely be important in its application in the metastatic setting. No significant financial relationships to disclose.
Clinical usefulness of an algorithm for the early diagnosis of spinal metastatic disease.
Authors: J Redmond, K E Friedl, P Cornett, M Stone, T O'Rourke, C B George
Journal: Journal of Clinical Oncology (1988)

We have previously reported an algorithm that invokes several imaging modalities in the early detection of metastatic and benign disease of the spine in patients with cancer (J Clin Oncol 4:576, 1986). The development of new lesions (shown by Tc99m bone scans) in cancer patients with normal neurological examinations is further evaluated with plain radiographs, spinal computed tomography (CT), and CT myelography (CT-M). Of 60 patients in the original study, 28% were diagnosed as having only benign disease and the remainder had spinal metastases. Thecal sac impingement was seen in 47% of patients with metastatic disease and disruption of the posterior vertebral cortex was noted in all patients with epidural compression. We now report the 2-year follow-up of 55 of these patients. Without treatment, the 17 patients diagnosed with benign disease have shown no evidence of local failure in the spine and median survival is greater than 27 months. Thirty-eight patients diagnosed with spinal metastases had a median survival time of 16.9 months. Radiation therapy directed by CT-M findings provided pain relief in 78% of patients with back pain and metastatic disease. No patient, including 19 with thecal sac impingement, developed clinical myelopathy. These results demonstrate the usefulness of an imaging algorithm for the early identification and distinction of spinal metastatic disease and benign disease in patients with cancer.
Examination of Oral Cancer Tissue for the Presence of the Proteins ICP 4, ICP 5, ICP 6, ICP 8, and gB of Herpes Simplex Virus Type 1<xref ref-type="fn" rid="FN2">2</xref>
Authors: E J Shillitoe, C B Hwang, S Silverman, J S Greenspan
Journal: JNCI Journal of the National Cancer Institute (1986)

Although patients with oral cancer have increased levels of antibody to herpes simplex virus type 1, the origin of the antigenic stimulation remains unknown. We have therefore looked for proteins of herpes simplex in oral squamous cell carcinomas by staining frozen sections with monoclonal antibodies to the proteins ICP 4, ICP 5, ICP 6, ICP 8, and gB. No staining was seen of the tumor cells of any of 11 oral cancer cases or of the epithelium of 29 other oral lesions, which included cases of leukoplakia, lichen planus, and aphthous ulcers. Frequent staining of mast cells was seen in the connective tissue associated with oral cancer when ascitic fluid was used as the source of monoclonal antibody, but such staining was not seen when the precipitated IgG fraction was used.
Response of meningeal Waldenström's macroglobulinemia to 2-chlorodeoxyadenosine.
Authors: A I Richards
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.9.2476 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7666113 Response of meningeal Waldenström's macroglobulinemia to 2-chlorodeoxyadenosine. A I RichardsxA I RichardsSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.9.2476 PDF "Response of meningeal Waldenström's macroglobulinemia to 2-chlorodeoxyadenosine.." Journal of Clinical Oncology, 13(9), p. 2476© 1995 by American Society of Clinical Oncology
Oral Nutrient Supplementation and Cognitive Function
Authors: Karin Yurko-Mauro, Edward Nelson, Norman Salem
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neoadyuvant radiochemotherapy for elder patients with stage II-III rectal cancer
Authors: A. Gomez Caamaño, E. Castro, U. Anido, A. Varela, Y. Vidal, T. Curiel, E. Fernandez, K. Areses, P. Calvo, R. López
Journal: Journal of Clinical Oncology (2008)

20531 Background: Rectal cancer incidence increase with age. Neoadyuvant radiochemotherapy is the standard treatment for locally advanced rectal cancer. Due to the fact that management of cancer in elderly is difficult because of age related conditions, we investigated the efficacy and safety profile of this treatment for stages II-III rectal cancer among elderly. Methods: Between January 1999 and July 2007,134 patients older than 70 years out of a total of 300 consecutive cases with locally advanced rectal adenocarcinoma (stage II: 25%; stage III: 75%) were treated with neoadyuvant conformational radiochemotherapy. Median age was 75 years (range 70–87) and they were in acceptable clinical condition (ECOG 0–1). The treatment consisted in radiation therapy up to a median total dose of 50 Gy (range 4,500–5,940 cGy) delivered using a conformational technique concomitant with 5-FU by continuous i.v. infusion (54 %), 5-FU bolus according to Mayo Clinic (20%), UFT oral (25%) and capecitabine (1%). Toxicity was scored according to CTCAE scale during the chemoradiation administration. Between radiotherapy and surgery the mean time was 7± 2,6 weeks, abdominoperineal resection was performed in 58 patients (43%) and anterior resection in 74 patients (55%). Results: 126 patients were able to support entire treatment (94%). 71% patients had downstaging (T y N downstaging was 70% and 71% respectively) and pathologic complete response were observed in 28 patients (21%). Pathologic stage were I in 40 patients (30%), II in 39 patients (29%) and III in 22 patients (16%). The majority adverse events were mild to moderate and grade 1–2 proctitis was the most common. Gastrointestinal acute toxicity grade 3–4 ocurred in 5 patients and haematological acute grade 3–4 were neutropenia in 2 patients. Conclusions: Neoadyuvant radiochemotherapy in elder patients with rectal cancer is effective and is well tolerated. Our data support to treat these patients depending on their performance status not on age. No significant financial relationships to disclose.
Development of an intervention algorithm in telemetrically supervised adaptation of positive airway pressure therapy for OSAS
Authors: Otto D. Schoch, Florent Baty, Jolanda Niedermann, Jochen J. Rüdiger, Martin H. Brutsche
Journal: European Respiratory Journal (2012)

Introduction:   The acceptance of positive airway pressure therapy (PAP) is a major clue to successful OSAS therapy. Telemedicine is a novel tool to supervise PAP use at the patient9s home. We report on treatment results with an intervention scheme developed to guide patients during the first month of telemetrically supervised PAP adaptation.    Methods:   After mask adaptation and explanation of the PAP devices (ResMed S9), newly diagnosed OSAS patients were equipped with telemedicine (ResTraxx Online TM , ResMed) for the first month of therapy. The automatically downloaded hours of PAP use and leak flow were checked 3 days per week. Patients received phone calls after 2 nights of  0.4L/s. Technical problems, number and duration of phone calls and CPAP use information were analysed.    Results:   During the study period, 73 OSAS patients received telemedicine for a total of 2045 nights. Minor technical problems with data transmission for 1 to 3 nights occurred in 12(16%) patients. The average PAP use was 4.2 +/- 3.4h/night. In 430 nights (21%), PAP was not used, hence, usage was 5.4+/-3.5h for nights on PAP. PAP use of >0h was detected in 74%, >4h in 55% of patients. A total of 174 calls, average duration 14 minutes, were performed in 53 (72%) patients, range 1 to 15 calls/patient. After 1 month, 62 (85%) OSAS patients continued PAP.    Conclusion:   Telemedicine for the introduction of PAP in OSAS is technically feasible. Our intervention algorithm resulted in phone calls for the majority of patients. To determine the direct effects of telemedicine on PAP acceptance, a randomised prospective study is necessary.
Radiation therapy for acquired immunodeficiency syndrome-related Kaposi's sarcoma.
Authors: L Y Chak, P S Gill, A M Levine, P R Meyer, J A Anselmo, Z Petrovich
Journal: Journal of Clinical Oncology (1988)

Twenty-four patients with acquired immunodeficiency syndrome (AIDS) received 80 courses of radiation therapy for Kaposi's sarcoma (KS). Pain and other symptoms due to mass effects were well controlled, but KS lesions often persisted in irradiated sites. Acute radiation toxicity to doses of approximately 2,000 cGy in ten fractions to the oral cavity and/or the foot were significant and may limit the dose and the efficacy of radiotherapy in patients with the epidemic form of KS.
Adult T-Cell Leukemia/Lymphoma Cells Were Eliminated By T Cells With Anti-CD38 Chimeric Antigen Receptor Through CD38 Expression Induced By All-Trans Retinoic Acid
Authors: Tetsumi Yoshida, Keichiro Mihara, Akira Kitanaka, Kazuya Shimoda, Kazuhiro Morishita, Yoshihiro Takihara, Tatsuo Ichinohe
Journal: Blood (2013)
Marrow transplantation for patients with thalassemia: results in class 3 patients
Authors: G Lucarelli, RA Clift, M Galimberti, P Polchi, E Angelucci, D Baronciani, C Giardini, M Andreani, M Manna, S Nesci, F Agostinelli, S Rapa, M Ripalti, F Albertini
Journal: Blood (1996)
The role of guanylyl cyclase in resistive breathing
Authors: Constantinos Glynos, Dimitris Toumpanakis, Constantinos Loverdos, Vassiliki Karavana, Zongmin Zhou, Maria Dettoraki, Tatiana Michailidou, Christina Magkou, Stamatios Theocharis, Andreas Papapetropoulos, Charis Roussos, Theodoros Vassilakopoulos
Journal: European Respiratory Journal (2013)

INTRODUCTION: Resistive breathing (RB) due to airflow limitation is the pathophysiologic hallmark of the chronic obstructive pulmonary disease (COPD). Smooth muscle tone constitutes an important determinant of airflow limitation. The principal pathway for smooth muscle tone involves nitric oxide (NO) signalling through activation of the soluble guanylyl cyclase (sGC). We aim to investigate the expression and downstream signalling of sGC in RB. METHODS: C57BL/6 wild type and sGC α 1 -/- mice underwent RB by placing a nylon band around the extrathoracic trachea segment, providing a 50% tracheal occlusion. Animals were divided into groups: 1. Mice with tracheal banding (TB) for 24 hrs and sham operated (control) mice. 2. sGC-α 1 -/- TB and control mice, 3. TB and control mice treated with inhaled sGC inhibitor, (ODQ; 20mg/Kg), 4. TB and control mice treated with sGC activator, BAY 58-2667(10µg/Kg; ip). RESULTS: Mice subjected to TB, exhibited a significant increase in BALF cellularity and protein content, consistent with acute inflammation. Using a forced oscillation technique, TB resulted in increased tissue elasticity and airway resistance and downward shift of the pressure-volume curve. TB reduced the expression of both α1 and β1 subunits of sGC, at mRNA and protein level, in the lung. A pronounced inflammation occurred after further reduction of sGC activity by ODQ or in sGC α 1 -/- mice. Pharmacological activation of sGC, using BAY 58-2667, 30 min before or 24 hrs after TB, reversed the injurious effects of RB on the lung. CONCLUSIONS: Our model of TB might offer new insights into a potentially protective role of the sGC in the context of resistive breathing.
Overall survival and clinically deficient quality of life in patients with esophageal cancer or Barrett's esophagus: A Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus Registry Consortium study.
Authors: R. C. Miller, P. J. Atherton, B. Kabat, M. B. Fredericksen, D. M. Geno, C. Deschamps, A. Jatoi, J. A. Sloan, Y. Romero
Journal: Journal of Clinical Oncology (2010)

4109 Background: Survival in patients (pts) with cancer has been linked to pt-reported clinically deficient quality of life (cdQOL). We examined patient-reported QOL and overall survival (OS) in pts with esophageal cancer (EC) or Barrett esophagus (BE) previously enrolled in the Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus Registry (EABE). Methods: Pts enrolled in the EABE between 09/01 and 01/09 returned a baseline questionnaire including a validated numerical analogue measure of overall QOL. Pts were categorized as having cdQOL at enrollment as defined by a score of ≤ 5 on a 0-10 scale. Kaplan-Meier methodology and Cox models explored OS in relation to cdQOL in pts with EC and BE. Results: 1,498 pts were included for analysis, 831 had BE (max follow-up of 7.5 years) and 667 had EC (max follow-up of 7.7 years). CdQOL was less likely in BE pts than EC pts (11% vs 28%). Five-year OS rate was significantly less in BE and EC for the cdQOL group (differences of 11% and 24%). Pts, where staging is available, having early stage (T1-2N0M0) EC (158 pts) or locally advanced stage EC (370 pts) had lower 5-year survival rate if they reported cdQOL (27% vs. 73%, HR=0.24, p<0.0001) and (13% vs. 25%, HR=0.58, p<0.0001). None of the pts with metastatic (TxNxM1b) disease (n=62) who had cdQOL survived to 5 years compared to 3% for those with non-cdQOL (p=0.56). Median survival was also significantly less in cdQOL early stage and locally advanced, but not metastatic, EC groups. Conclusions: A deficit in QOL is strongly associated with OS in patients with BE and nonmetastatic EC. CdQOL is a significant predictor of OS in patients with EC and should be considered as a stratification factor in the design of clinical trials. Predictor N (events) 5-year survival rate Cox proportional hazard p value HR (95% CI) BE (N = 831, 77 events) QOL ≤ 5 (cdQOL)QOL > 5 91 (18) 740 (59) 77% (66%–89%)88% (85%–91%) <0.0001 0.30 (0.18–0.51) EC (N = 667, 350 events) QOL ≤ 5 (cdQOL)QOL>5 191 (130)476 (220) 14% (9%–23%)38% (33%–45%) <0.0001 0.46 (0.37–0.58) No significant financial relationships to disclose.
Extensive Amplification and Self-Renewal of Human Primitive Hematopoietic Stem Cells From Cord Blood
Authors: Wanda Piacibello, Fiorella Sanavio, Lucia Garetto, Antonella Severino, Daniela Bergandi, Jessica Ferrario, Franca Fagioli, Massimo Berger, Massimo Aglietta
Journal: Blood (1997)
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer.
Authors: M Markman, T Hakes, R Barakat, J Curtin, L Almadrones, W Hoskins
Journal: Journal of Clinical Oncology (1996)

PURPOSE To examine the short-term and long-term results of paclitaxel therapy in patients with advanced heavily pretreated, cisplatin-refractory ovarian cancer. PATIENTS AND METHODS The results of treatment for patients entered onto National Cancer Institute (NCI) Treatment Referral Center protocol 9103 at the Memorial Sloan-Kettering Cancer Center (MSKCC) were reviewed to evaluate toxicity, efficacy, and survival. RESULTS Of 46 individuals with measurable disease treated on the protocol at MSKCC, the objective response rate was only 4%. However, the 2- and 3-year survival rates for all 103 patients (including both measurable and nonmeasurable populations) entered onto this study at MSKCC were 18% and 11%, respectively. Twenty-one percent of patients received &gt; or = six courses of paclitaxel, which suggests treatment-related stabilization of disease may have had a greater impact on the natural history of the malignancy than indicated by the objective response rate. CONCLUSION This experience supports the hypothesis that a more prolonged delivery of paclitaxel (ie, &gt; six courses), a cell-cycle-specific cytotoxic agent with limited or no cumulative toxicity, may result in an improved therapeutic outcome in ovarian cancer. This concept will need to be tested in a randomized phase 3 clinical trial.
Randomized, Dose-Ranging Phase Ii Trial of Nivolumab for Metastatic Renal Cell Carcinoma (Mrcc)
Authors: R.J. Motzer, B.I. Rini, D.F. McDermott, B. Redman, T. Kuzel, M.R. Harrison, U.N. Vaishampayan, H. Drabkin, S. George, T. Logan, K. Margolin, E.R. Plimack, I. Waxman, A. Lambert, H. Hammers
Journal: Annals of Oncology (2014)
Macrophages promote prosclerotic responses in cultured rat mesangial cells
Authors: I Z Pawluczyk, K P Harris
Journal: Journal of the American Society of Nephrology (1997)

Glomerulosclerosis is the final outcome of a number of different causes of glomerular injury, during which the structures of the glomerulus are obliterated by extracellular matrix. Accumulating evidence suggests that infiltrating macrophages play a pivotal role in the progression to glomerulosclerosis. The present study defines the role played by macrophages at both cellular and molecular levels in the initiation of the sclerotic process in cultured rat mesangial cells. Macrophage-conditioned medium (MPCM) generated from thioglycollate-elicited, lipopolysaccharide-stimulated macrophages upregulated mesangial cell fibronectin production in a dose- and time-dependent manner, independently of cell proliferation. Immunoprecipitation of metabolically labeled 35S-fibronectin confirmed that the matrix protein was synthesized de novo. The genes for fibronectin and the matrix proteins laminin and collagen IV were also found to be upregulated 2.86 +/- 0.24-, 4.94 +/- 0.17-, and 3.03 +/- 0.31-fold over controls, respectively (P < 0.001). Macrophage modulation of matrix turnover was suggested by an upregulation of both transin and tissue inhibitor of metalloproteinase-1 gene transcription. Transforming growth factor (TGF) beta1, platelet-derived growth factor, tumor necrosis factor (TNF) alpha, or interleukin (IL)-1beta could not be detected in the MPCM per se; however, TGFbeta1 and platelet-derived growth factor AB were found to be secreted into mesangial cell culture supernatants. Secretion was augmented 1.69 +/- 0.16- and 2.28 +/- 0.28-fold, respectively (both P < 0.001), in response to MPCM. Northern blot analysis demonstrated that protein secretion had been preceded by upregulation of the genes for these cytokines (2.2 +/- 0.4-fold [P < 0.001] and 5.7 +/- 1.2-fold [P < 0.004], respectively). Incubation of MPCM with either neutralizing antibody or the growth factor receptor antagonist suramin demonstrated that TGFbeta1 played a significant, although minor, role in MPCM-stimulated fibronectin production. In conclusion, this study provides compelling evidence for a direct role of macrophages in the progression to glomerulosclerosis.
Role of general practitioners in NHS must not be undervalued
Authors: T. Hennell, A. Majeed
Journal: BMJ (1999)

Proportions of cases (babies with neonatal encephalopathy) and controls having complicated* and uncomplicated † deliveries in Badawi et al's study No (%) of cases (n=164) No (%) of controls (n=400) Unadjusted odds ratio (95% CI) Complicated delivery 79 (48) 101 (25) 2.75 (1.88 to 4.02) Uncomplicated delivery 85 (52) 299 (75) 0.36 (0.25 to 0.53) *Complicated deliveries: instrumental deliveries
The surveillance of communicable diseases in the European Union – a long-term strategy (2008-2013)
Authors: A Amato-Gauci, A Ammon
Journal: Eurosurveillance (2008)

This article presents the steps and considerations that led to the development of the European Centre for Disease Prevention and Control s (ECDC) long-term strategy for the surveillance of communicable diseases in the European Union (EU) for the years 2008 to 2013. Furthermore, it outlines the key features of the strategy that was approved by the ECDC s Management Board in December 2007.